In antitumor treatment, metformin mainly inhibits mammalian target of rapamycin and its downstream target through modulating mitochondrial functions and the expression of the PI3k/Akt pathway, thereby curbing tumor cell survival [33]. This evidence concerns the gene AKT1 and neoplasm.